GlassScriptPhysician profile
Revel Porter
NPI 1861488348
$12,341.95
in general payments reported to CMS, 2019-2025
56 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,864 · 2020: $1,950 · 2021: $2,575 · 2022: $1,911 · 2023: $1,348 · 2024: $1,249 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,041.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,197.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,183.35 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,180.94 | 2019-2024 | |
| Amgen INC. | $976.58 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $796.67 | 2019-2022 | |
| Astellas Pharma US INC | $766.98 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $528.13 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $497.59 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $491.88 | 2019-2025 | |
| Novo Nordisk INC | $475.12 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.42 | 2019-2024 | Ofev, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.24 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $375.46 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $306.15 | 2019-2022 | |
| Daiichi Sankyo INC. | $238.34 | 2020-2024 | Injectafer |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Revel Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.